Accueil / Communiqués / FSD Pharma Congratulates Cannara Biotech for Its Listing and Commencement of Trading on the CSE

FSD Pharma Congratulates Cannara Biotech for Its Listing and Commencement of Trading on the CSE

Monday, January 14th 2019 at 1:00pm UTC

TORONTO–(BUSINESS WIRE)– FSD Pharma Inc. (« FSD » or the « Company ») (CSE: HUGE) (OTCQB: FSDDF)
(FRA: 0K9) would like to congratulate Cannara Biotech Inc. (“Cannara”)
for its listing approval and commencement of trading on the Canadian
Securities Exchange (« CSE ») today under the stock symbol « LOVE ». FSD
Pharma, directly or indirectly, acquired ownership of 85,003,750 common
shares (« Common Shares ») of the Issuer, representing 12.25% of the
issued and outstanding Common Shares of the Issuer.

Anthony Durkacz, Co-Chairman of the Board and Co-Founder of FSD, said,
« I want to congratulate Zohar Krivorot and his team at Cannara for
achieving this significant milestone and for their ongoing efforts to
build out the largest indoor cannabis grow facility in Quebec. The
listing of Cannara’s shares on the CSE today will give investors the
chance to share in the company’s continued success and growth. FSD fully
supports Cannara’s strategic vision and expansion plans and intends to
continue working in partnership with Cannara to take advantage of
opportunities that benefit both companies.”

About Cannara Biotech Inc.

Cannara Biotech is building the largest indoor cannabis cultivation
facility in Quebec, a modern and secure 625,000 square foot facility
located in Farnham, less than 45 minutes from downtown Montreal.
Leveraging Quebec’s low electricity costs, Cannara will produce
high-grade indoor cannabis and derivative products for the Canadian and
international markets. Working with partners from various industries,
Cannara will generate licensing revenues, rental revenues and revenue
streams from joint-venture arrangements leveraging this highly valuable
property. For more information, visit our website: www.cannara.ca

About FSD Pharma

FSD Pharma is focused on the development of the highest quality indoor
grown, pharmaceutical grade cannabis and on the research and development
of novel cannabinoid-based treatments for several central nervous system
disorders, including chronic pain, fibromyalgia and irritable bowel
syndrome. The Company has 25,000 square feet available for production at
its Ontario facility with an additional 220,000 square feet currently in
development (with an estimated cost of $250 per square foot to be
completed in 2019).

FSD facilities sit on 72 acres of land with 40 acres primed for
development and an expansion capability of up to 3,896,000 square feet.

FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under
the Cannabis Act and Regulations, having received its cultivation
license on October 13, 2017. FV Pharma’s vision is to transform its
current headquarters in a Kraft plant in Cobourg, Ontario into the
largest hydroponic indoor grow facility in the world. FV Pharma intends
to cover all aspects of this exciting new industry, including
cultivation, legal, processing, manufacturing, extracts and research and
development.

Forward-Looking Information

Neither the Canadian Securities Exchange nor its regulation
services provider accept responsibility for the adequacy or accuracy of
this release.

Certain statements contained in this press release constitute
forward-looking information. These statements relate to future events or
future performance. The use of any of the words « could », « intend »,
« expect », « believe », « will », « projected », « estimated » and similar
expressions and statements relating to matters that are not historical
facts are intended to identify forward-looking information and are based
on the Corporation’s current belief or assumptions as to the outcome and
timing of such future events. Actual future results may differ
materially. In particular, this release contains forward-looking
information relating to the development of the Corporation’s indoor
cannabis facility and its business goals and objectives. The
forward-looking information contained in this press release is made as
of the date hereof, and the Corporation is not obligated to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable securities laws. Because of the risks, uncertainties and
assumptions contained herein, investors should not place undue reliance
on forward looking-information. The foregoing statements expressly
qualify any forward-looking information contained herein.

Contacts

Additional Information:
Zeeshan Saeed, President and
Founder, FSD Pharma Inc.
Email: zeeshan@fsdpharma.com
Telephone:
(416) 854-8884
or
Investor Relations
Email: IR@fsdpharma.com
Website:
www.fsdpharma.com
or
Media
Relations

Ned Berkowitz
Email: Ned.Berkowitz@russopartnersllc.com
Tel:
(646) 942-5629

Source: FSD Pharma Inc.


Voir aussi

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Friday, January 18th 2019 at 9:05pm UTC WALTHAM, Mass.–(BUSINESS WIRE)– Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today …